All In Biotech

Drug Trial Radar · NCT05912075

Preoperative Radiotherapy And ASTX660 in Rectum Cancer

An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

Last checked: Nov 19, 2026Latest source record: Feb 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Dec 19, 2023

Primary completion

Jan 1, 2028

Study completion Jan 2029

Sponsor

Lead sponsor
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Compare two arms: * Chemotherapy followed by tolinapant (ASTX660) in combination with Long-Course Radio Chemotherapy (LCRT), and * Tolinapant (ASTX660) in combination with Short-Course Radiotherapy (SCRT) followed by chemotherapy For each patient, the treatment arm will be allocated on the following basis: patients will be allocated to the chemotherapy followed by LCRT arm unless they present at least one of the following criteria: contraindication to receive mFOLFIRINOX (including intolerance to irinotecan and UGT1A1\*28 polymorphism), age \> 75, general condition incompatible with the radiotherapy schedule of LCRT. In such case, patients will be allocated to the SCRT arm. Tolinapant (ASTX660) will be administered orally once a day for 7 consecutive days every other week during 10 weeks (One week On / One week Off during 10 weeks). Both treatment arms will have a dose escalation part to determine the MTD and/or RP2D, followed by an expansion part where up to 21 subjects will be dosed at the RP2D. Both arms will enroll simultaneously.

Conditions

  • Locally-advanced Rectal Cancer

Interventions

  • mFOLFIRINOXDrug

    prior to tolinapant (ASTX660) for 6 cycles over 12 weeks

  • Pelvic radiotherapy LCRTRadiation

    50-Gy total dose in 25 daily fractions of 2 Gy (5 days per week from Monday to Friday) for 5 weeks

  • CapecitabineDrug

    800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy

  • TOLINAPANT (ASTX660)Drug

    starting from 14 days before the first dose of radiotherapy, for 10 weeks.

  • Pelvic radiotherapy SCRTRadiation

    total dose of 25 Gy, in 5 daily fractions of 5 Gy for 1 week (5 days from Monday-Friday)

  • FOLFOX4Drug

    given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy

  • CAPOXDrug

    every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities (DLTs)Time frame: during the 10 weeks of tolinapant (ASTX660) treatment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Centre Léon Bérard

    Lyon, Rhöne, France · Not yet recruiting

  • Gustave Roussy

    Villejuif, Val De Marne, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.